Esperion Therapeutics Inc (ESPR) Shares Sold by BlackRock Inc.

BlackRock Inc. lessened its holdings in shares of Esperion Therapeutics Inc (NASDAQ:ESPR) by 1.1% in the 1st quarter, Holdings Channel reports. The firm owned 1,488,597 shares of the biopharmaceutical company’s stock after selling 16,798 shares during the quarter. BlackRock Inc. owned approximately 0.06% of Esperion Therapeutics worth $107,671,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. BB Biotech AG raised its holdings in Esperion Therapeutics by 2.1% in the 1st quarter. BB Biotech AG now owns 2,412,964 shares of the biopharmaceutical company’s stock valued at $174,530,000 after acquiring an additional 50,000 shares in the last quarter. Northern Trust Corp raised its holdings in Esperion Therapeutics by 0.9% in the 1st quarter. Northern Trust Corp now owns 579,402 shares of the biopharmaceutical company’s stock valued at $41,909,000 after acquiring an additional 5,025 shares in the last quarter. Millennium Management LLC raised its holdings in Esperion Therapeutics by 1,062.7% in the 4th quarter. Millennium Management LLC now owns 387,947 shares of the biopharmaceutical company’s stock valued at $25,542,000 after acquiring an additional 354,580 shares in the last quarter. Columbus Circle Investors raised its holdings in Esperion Therapeutics by 192.7% in the 1st quarter. Columbus Circle Investors now owns 254,704 shares of the biopharmaceutical company’s stock valued at $18,423,000 after acquiring an additional 167,675 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. raised its holdings in Esperion Therapeutics by 25.5% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 238,384 shares of the biopharmaceutical company’s stock valued at $15,695,000 after acquiring an additional 48,485 shares in the last quarter. 98.39% of the stock is owned by institutional investors and hedge funds.

Several research firms have commented on ESPR. ValuEngine cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, June 21st. BidaskClub raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 21st. UBS Group set a $75.00 price target on Esperion Therapeutics and gave the company a “buy” rating in a report on Wednesday, May 16th. Credit Suisse Group cut their price target on Esperion Therapeutics from $108.00 to $73.00 and set an “outperform” rating for the company in a report on Friday, May 4th. Finally, JPMorgan Chase & Co. cut Esperion Therapeutics from a “neutral” rating to an “underweight” rating and cut their price target for the company from $100.54 to $41.00 in a report on Thursday, May 3rd. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $89.08.

In other Esperion Therapeutics news, major shareholder Target N. V. Biotech purchased 50,000 shares of the firm’s stock in a transaction that occurred on Friday, May 18th. The shares were acquired at an average cost of $42.24 per share, for a total transaction of $2,112,000.00. Following the transaction, the insider now directly owns 2,872,964 shares in the company, valued at $121,353,999.36. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Target N. V. Biotech purchased 130,000 shares of the firm’s stock in a transaction that occurred on Monday, May 21st. The shares were acquired at an average price of $40.11 per share, for a total transaction of $5,214,300.00. Following the completion of the transaction, the insider now owns 2,872,964 shares in the company, valued at $115,234,586.04. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 360,000 shares of company stock worth $14,216,100. Corporate insiders own 32.50% of the company’s stock.

ESPR stock opened at $38.50 on Friday. Esperion Therapeutics Inc has a 1-year low of $33.06 and a 1-year high of $82.68. The company has a market capitalization of $1.02 billion, a PE ratio of -5.52 and a beta of 2.37.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Wednesday, May 2nd. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.17). During the same quarter in the prior year, the company posted ($1.80) earnings per share. sell-side analysts predict that Esperion Therapeutics Inc will post -6.31 earnings per share for the current year.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics Inc (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply